Virtus Investment Advisers’s Celldex Therapeutics CLDX Stock Holding History

Virtus Investment Advisers’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$389K	Buy	10,464 +553	+6%	+$17.9K	0.09%	292
2026 Q1	$314K	Buy	9,911 +240	+2%	+$6.54K	0.09%	271
2025 Q4	$263K	Buy	9,671 +4,079	+73%	+$107K	0.07%	306
2025 Q3	$145K	Buy	5,592 +971	+21%	+$22.5K	0.04%	380
2025 Q2	$94K	Sell	4,621 -1,587	-26%	-$30.9K	0.03%	357
2025 Q1	$113K	Buy	+6,208	New	+$139K	0.03%	402

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Virtus Investment Advisers's CLDX Position: Q2 2026 in Review

Virtus Investment Advisers increased its Celldex Therapeutics (CLDX) stake by 5.6% in Q2 2026, buying an estimated $17.9K and bringing the position to 10,464 shares worth $389K. The position accounts for 0.09% of the portfolio, ranked #292.

Virtus Investment Advisers first reported a position in CLDX in Q1 2025 and has held it in 6 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

Virtus Investment Advisers held 10,464 shares of Celldex Therapeutics worth $389K as of Q2 2026.
Virtus Investment Advisers bought 553 Celldex Therapeutics shares in Q2 2026, an estimated $17.9K.
Celldex Therapeutics made up 0.09% of Virtus Investment Advisers's portfolio in Q2 2026, its #292 holding.
Virtus Investment Advisers first reported a position in Celldex Therapeutics in Q1 2025 and has held it in 6 quarters since.
253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.